StockNews.AI
ALGS
StockNews.AI
146 days

Aligos Therapeutics Presents Positive Data at APASL 2025

1. Aligos presents positive data from APASL 2025 conference. 2. ALG-000184 shows potential as first-line therapy for chronic Hepatitis B. 3. ALG-055009 achieves significant liver fat reduction in MASH patients. 4. Patients on ALG-055009 had fewer gastrointestinal issues than placebo. 5. No viral resistance observed with ALG-000184 treatment.

10m saved
Insight
Article

FAQ

Why Very Bullish?

Positive clinical data typically drives increased investor confidence and stock prices. Historical precedents reveal strong price movements following similar announcements in biotech firms.

How important is it?

The data discusses significant advancements in Hepatitis B and MASH treatments, which are core to ALGS's business. The strong positive results have the potential to drive long-term stock price improvements.

Why Long Term?

The successful clinical data may lead to market approval and increased revenues over time. Long-term value may grow as these treatments are adopted in the market.

Related Companies

GILDMRNAAVIR
March 26, 2025 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. “We are pleased to present preliminary data out to 96 weeks in our Phase 1 study of ALG-000184, which continues to demonstrate first-/best-in-class reductions in important HBV markers,” stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. “Additionally, the HERALD data from the Phase 2a study of ALG-055009 in MASH subjects demonstrated robust reductions in liver fat, with a subgroup analysis in subjects on stable GLP-1 agonist therapy, showing a potential role for ALG-055009 in combination with other therapies.” Two oral presentations will highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B virus (HBV) infection in both HBeAg-positive and HBeAg-negative subjects, demonstrating the potential for the molecule to become first-line therapy for chronic suppression and the backbone for regimens aimed at functional cure. Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated HBV DNA suppression (

Related News